About us
A neuroscience-focused biopharmaceutical company dedicated to delivering life-changing therapeutics for people in need
“At Xenon, we are united by a common mission: to deliver innovative medicines that provide a brighter future for people living with neurological and psychiatric disorders. This purpose has driven our scientific curiosity and innovation in ion channel science, and it is enabling us to build a world-class, fully integrated company capable of turning scientific breakthroughs into life-changing medicines. The progress we’ve made since our founding fuels our optimism for the transformative potential of our pipeline to help patients who have been underserved for too long. From our science to our community partnerships, we are committed to making a meaningful impact and reshaping treatment paradigms.”
Ian MortimerPresident and CEO
Meet our team
Our company is guided by a leadership team with decades of combined experience in drug discovery, development, and commercialization. Driven by the pursuit of breakthrough science and patient-centered care, our multidisciplinary team blends scientific excellence with strategic vision.
Our story
Heritage in ion channel science
Xenon was founded in 1996 with a focus on discovering new genetic targets to treat human disease. Soon, we became inspired by the opportunity to translate our genetic insights into life-changing medicines, prompting us to establish our own drug discovery and clinical development capabilities and pursue collaborations with multiple premier biopharmaceutical companies. One of our early areas of focus was the sodium channel Nav1.7, which launched our decades-long scientific commitment to ion channel drug discovery, particularly those expressed in the central and peripheral nervous system.
In 2014, we became a publicly traded company in the US with the intent to become a fully integrated biotechnology company. We started to narrow the focus of our proprietary pipeline to neuroscience, leveraging our heritage in genetics and expertise in ion channel biology.
Today, we have one of the deepest pipelines of ion channel modulators in the industry. With a robust Phase 3 program across epilepsy and depression for our lead candidate, azetukalner, early-stage programs in pain, and a broad pipeline targeting sodium and potassium channels, we are primed to sustainably deliver innovative medicines to people in need.
2020s
2000s
